Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund which supports early-stage companies with Series A investments across biotech, medtech and healthtech. Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005. Chris serves on a number of Boards of life sciences companies and speaks at industry conferences on a wide range of important issues. Chris is also on the Board of Directors of MassBio, served as a Senior Advisor for the Boston Consulting Group and is a member of the Corporate Relations Board for the Keck Graduate Institute.

Before founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.

Kendalle Burlin O’Connell is a seasoned and effective executive who has received wide acclaim for her leadership of MassBio, the world’s largest biopharma membership organization, where she drives the strategy to grow the industry and support member companies as CEO and president. To better serve the entire life cycle of biopharma companies, Kendalle has expanded MassBio’s innovation offerings to include partnering and investor events, an entrepreneurial accelerator, and a network for founders and chief executives. As part of MassBio’s commitment to realizing a more diverse and equitable life sciences industry, Kendalle was the driving force behind the organization’s launch of the non-profit Bioversity and the opening of its first workforce training center in Dorchester where graduates are prepared for rewarding entry-level careers at local life sciences companies. Kendalle has been an outspoken advocate for the industry in policy debates about state government support for the expansion of the life sciences in Massachusetts, the federal government’s intervention into biopharma innovation, and efforts to improve the affordability and accessibility of life-changing medicines, just to name a few. Kendalle has earned numerous accolades for her leadership, including top recognitions from Boston Magazine and the Boston Business Journal, and serves on the Boards of The Boston Foundation and the American Cancer Society, where she is Chair for the Eastern New England region, among others.